Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.40 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476711 | 0.86 | PTGS1 (0.39) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL476692 | 0.85 | TLR7 (0.40) | RECQLKCNJ5KCNJ3MEN1KMT2A | |
| SCHEMBL476681 | 0.85 | MEN1 (0.39) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL476619 | 0.85 | ALDH1A1 (0.39) | RECQLKCNJ5KCNJ3MEN1KMT2A | |
| SCHEMBL476538 | 0.85 | SMN1; SMN2 (0.40) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL476594 | 0.84 | ALDH1A1 (0.37) | KCNJ5KCNJ3MEN1KMT2ACYP1A2 | |
| SCHEMBL476636 | 0.83 | HTR7 (0.39) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL476641 | 0.79 | MEN1 (0.61) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5675132 | 0.79 | MEN1 (0.44) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5672286 | 0.78 | CCR2 (0.37) | MEN1KMT2AALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951225-B1 | 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-7741363-B2 | 3-Acylindole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-06-22 | — | — | US | disclosed |
| EP-1567150-B1 | DERIVATIVES OF INDOLE-3-CARBOXAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2009-08-12 | — | — | EP | disclosed |
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-06 | — | — | US | disclosed |
| US-7202268-B2 | Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-04-10 | — | — | US | disclosed |
| US-7138424-B2 | Indole derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2006-11-21 | — | — | US | disclosed |
| US-20060089345-A1 | Indole derivatives, method for preparating same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | US | disclosed |
| US-6995184-B2 | Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors | SANOFI-AVENTIS (FR) | 2006-02-07 | — | — | US | disclosed |
| US-20050288356-A1 | Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2005-12-29 | — | — | US | disclosed |
| EP-1507758-B1 | INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS | SANOFI AVENTIS (FR) | 2005-11-02 | — | — | EP | disclosed |
| EP-1339679-B1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI AVENTIS (FR) | 2005-08-10 | — | — | EP | disclosed |
| EP-1507758-A2 | INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS | Sanofi-Aventis (FR) | 2005-02-23 | — | — | EP | disclosed |
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| WO-2003097597-A2 | INDOLE DERIVATIVES AND THE USE THEREOF AS CB2 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2003-11-27 | — | — | WO | disclosed |
| EP-1339679-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042269-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI-SYNTHELABO (FR) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288356-A1 | Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics | IDO1, IDO2, TDO2 | RECQL 3211/4885KCNJ5 2369/4885KCNJ3 1438/4885 |
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | CNR2, CNR1, GPR52 | RECQL 4704/4885KCNJ5 532/4885KCNJ3 481/4885 |
| US-20060089345-A1 | Indole derivatives, method for preparating same and pharmaceutical compositions containing same | CNR2, CNR1, IDO2 | RECQL 4761/4885KCNJ5 175/4885KCNJ3 278/4885 |
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | F12, ECI1, NQO2 | RECQL 420/4885KCNJ5 1347/4885KCNJ3 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.